Dana-Farber Cancer Institute | Strategic Alliance Partners

Count Me In, a patient-partnered research initiative led by Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, is launching a project focused on translocation renal cell carcinoma.

Daniel J. DeAngelo, MD, PhD, discusses the clinical implications of findings from the PATHFINDER trial of avapritinib in advanced ​​systemic mastocytosis.

Treatment with casdatifan was well tolerated and showed meaningful clinical activity in patients with previously treated ccRCC.

Dana-Farber investigators found that normally defunct viral genes that lie dormant in the human genome can be activated in ccRCC.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Lakshmi Nayak, MD, discusses the mechanism of action of emavusertib and the study of this drug relapsed/refractory primary and secondary CNS lymphoma.

Eric S. Winer, MD, discusses the efficacy of emavusertib in patients with relapsed/refractory AML harboring FLT3 and/or spliceosome factor mutations.

Kimberly Stegmaier, MD, was recently named Chair of Pediatric Oncology at Dana-Farber Cancer Institute.

Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Daniel J. DeAngelo, MD, PhD, details how the split dosing of obe-cel yields reduced toxicities and makes it a unique CAR T-cell therapy for relapsed/refractory ALL.

Patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma generated successful responses after a personalized cancer vaccine.

The model, called EpiBERT, was inspired by BERT, a deep learning model designed to understand and generate human-like language.

Toni K. Choueiri, MD, discusses the significance of targeting HIF-2α using NKT2152 in previously treated advanced clear cell renal cell carcinoma.

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Patients with evidence of residual cancer in their blood after surgery, may benefit from adding of celecoxib to post surgery treatment.

Toni Choueiri, MD, discusses the unique features of NKT2152, the agent’s safety profile in RCC, and future research directions across GU oncology.

Researchers at Dana-Farber Cancer Institute have developed a breakthrough method to detect inflammation in the body using positron emission tomography (PET) imaging.

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management

Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics to advance scientific investigation and clinical care for RAS-driven cancers.

Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

Daniel DeAngelo, MD, PhD, discusses the FDA approval of blinatumomab in the consolidation phase in CD19-positive, Ph-negative B-cell precursor ALL.